Emergent awarded $187 million anthrax vaccine contract
This article was originally published in Scrip
Executive Summary
Emergent BioSolutions has secured a contract with the US Biomedical Advanced Research and Development Authority (BARDA) for up to $186.6 million to develop a recombinant protective antigen (rPA) anthrax vaccine.